# Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

> **NCT03718429** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 86 (actual)

## Conditions studied

- Coronary Artery Disease
- Peripheral Arterial Disease
- Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban 2.5 mg Tablet

## Key facts

- **NCT ID:** NCT03718429
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-08-30
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2022-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03718429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03718429, "Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03718429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*